文献速递血栓与止血造血干细胞移植与细胞治疗

血液系统恶性肿瘤患者预防性使用氨甲环酸:一项安慰剂对照随机临床试验

Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial.
PubMed 文献 · Blood · 2022-01-01

该随机双盲安慰剂对照试验纳入337例接受化疗或造血干细胞移植的血液系统恶性肿瘤患者,比较预防性口服1300 mg或静脉1000 mg氨甲环酸(TXA)每日三次与安慰剂的效果。结果显示TXA组与安慰剂组WHO≥2级出血发生率分别为50.3%和54.2%,调整OR为0.83(95%CI 0.50-1.34;P=0.44),无统计学显著差异。

要点

  • 预防性TXA未显著降低WHO≥2级出血风险,调整OR 0.83(95%CI 0.50-1.34;P=0.44)。
  • 血小板输注量、无出血存活天数、血栓事件及出血相关死亡两组均无显著差异。
  • 最常见不良事件为腹泻、发热性中性粒细胞减少、乏力及恶心,两组发生率相近。

核心结论

  • 在血液系统恶性肿瘤接受化疗或造血干细胞移植的患者中,与安慰剂相比,预防性使用TXA未显著降低WHO≥2级出血风险。

研究设计与样本

  • 随机双盲安慰剂对照临床试验,2016年6月至2020年6月开展,筛查3120例成人,入组356例,随机337例(平均年龄53.9岁;女性141例[41.8%]),TXA组168例、安慰剂组169例。
  • TXA给药方案为口服1300 mg或静脉1000 mg,每日三次,最长30天;当血小板计数低于30000/µL时激活330例,279例(83%)完成结局确认。

主要发现

  • 激活后30天内WHO≥2级出血在TXA组为50.3%(73/145),安慰剂组为54.2%(78/144),调整OR 0.83(95%CI 0.50-1.34;P=0.44)。
  • 血小板输注平均次数平均差0.1(95%CI -1.9至2.0),无≥2级出血的平均存活天数平均差0.8天(95%CI -0.4至2.0),均无统计学显著差异。
  • 血栓事件TXA组6/163(3.7%),安慰剂组9/163(5.5%);出血相关死亡两组无显著差异。
  • 常见不良事件:腹泻TXA组116/164(70.7%) vs 安慰剂组114/163(69.9%);发热性中性粒细胞减少111/164(67.7%) vs 105/163(64.4%);乏力106/164(64.6%) vs 109/163(66.9%);恶心104/164(63.4%) vs 97/163(59.5%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Evidence of the effectiveness of prophylactic use of tranexamic acid (TXA) in thrombocytopenia is lacking. To determine whether TXA safely reduces bleeding incidence in patients undergoing treatment for hematologic malignancies, a randomized, double-blind clinical trial was conducted from June 2016 through June 2020. Of 3120 screened adults, 356 patients were eligible and enrolled, and 337 patients (mean age, 53.9; 141 [41.8%] women), randomized to 1300 mg TXA orally or 1000 mg TXA through IV (n = 168) vs placebo (n = 169) thrice daily for maximum 30 days. Three hundred thirty patients were activated when their platelet counts fell below 30 000 per µL; 279 (83%) had complete outcome ascertainment. World Health Organization (WHO) grade ≥2 bleeding was observed in the 30 days following activation in 50.3% (73/145) and 54.2% (78/144) of patients in the TXA and placebo groups, with an adjusted odds ratio of 0.83 (95% confidence interval [CI], 0.50-1.34; P = .44). There was no statistically significant difference in the mean number of platelet transfusions (mean difference, 0.1; 95% CI, -1.9 to 2.0), mean days alive without grade ≥2 bleeding (mean difference, 0.8; 95% CI, -0.4 to 2.0), thrombotic events (6/163 [3.7%] TXA, 9/163 [5.5%] placebo), or deaths due to serious bleeding. Most common adverse events were: diarrhea (116/164 [70.7%] TXA and 114/163 [69.9%] placebo); febrile neutropenia (111/164 [67.7%] TXA, 105/163 [64.4%] placebo); fatigue (106/164 [64.6%] TXA, 109/163 [66.9%] placebo); and nausea (104/164 [63.4%] TXA, 97/163 [59.5%] placebo). Among patients with hematologic malignancy undergoing chemotherapy or hematopoietic stem cell transplantation, prophylactic treatment with TXA compared with placebo did not significantly reduce the risk of WHO grade ≥2 bleeding.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Gernsheimer TB, Brown SP, Triulzi DJ, et al. Prophylactic tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized clinical trial. Blood. 2022. PMID: 35667085. doi:10.1182/blood.2022016308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。